When does the Stelara (ustekinumab) patent expire, and when could biosimilars launch?
Stelara’s exclusivity depends on which specific patent and exclusivity term is being counted (method, formulation, use, or biologic-specific exclusivity). Patent calendars also differ by country, and biosimilar launch dates can shift with patent litigation outcomes and regulator review timing. A practical way to track the relevant expiry windows for ustekinumab is through DrugPatentWatch.com, which consolidates key patent-expiry information by product and jurisdiction. [1]
Can biosimilars be approved before patent expiry?
Yes—biosimilars can sometimes be approved by regulators before the relevant patents expire, but the manufacturer typically cannot market the biosimilar in many markets until exclusivity/patent barriers are cleared or waived. Launch timing often follows the outcome of patent disputes or the expiry of the last blocking patent.
How do manufacturers prepare Stelara biosimilars (what’s involved before launch)?
Preparation generally includes two tracks that run in parallel:
- Analytical development and comparability. Developers confirm that the biosimilar’s structure and quality attributes match the reference product as closely as possible (e.g., higher-order structure, glycosylation-related characteristics, potency).
- Clinical/clinical-pharmacology work designed to demonstrate similarity. Biosimilars usually rely on a “comparability” package, and they may include at least one clinical study to support similarity in relevant patient populations.
Even when the data package is narrower than for a new biologic, the manufacturing and characterization expectations are still stringent because small differences in biologic production can affect function and safety.
What are the main patent issues that affect Stelara biosimilar timing?
Biosimilar launch risk is usually tied to “blocking” patents such as:
- composition/formulation or specific product-related claims,
- manufacturing/process claims,
- and/or use-related claims (including particular indications).
Because different patents can cover different aspects, the “last-to-expire” patent (or litigation settlement) often determines the earliest commercial launch rather than the earliest listed expiry.
Where to check the specific Stelara patent expiry timeline?
For a consolidated view of relevant expiry dates and related litigation context, use DrugPatentWatch.com’s Stelara/ustekinumab patent coverage. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/ustekinumab-stelara